<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886065</url>
  </required_header>
  <id_info>
    <org_study_id>16-237</org_study_id>
    <nct_id>NCT02886065</nct_id>
  </id_info>
  <brief_title>A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM</brief_title>
  <official_title>A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OncoPep, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is studying a targeted therapy as a possible treatment for Smoldering&#xD;
      Multiple Myeloma.&#xD;
&#xD;
      The following intervention will be involved in this study:&#xD;
&#xD;
        -  Lenalidomide&#xD;
&#xD;
        -  Citarinostat (CC-96241)&#xD;
&#xD;
        -  PVX-410&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase I clinical trial, which tests the safety of an investigational&#xD;
      intervention and also tries to define the appropriate dose of the investigational&#xD;
      intervention to use for further studies. &quot;Investigational&quot; means that the intervention is&#xD;
      being studied.&#xD;
&#xD;
      In this research study, the investigators are studying Smoldering Multiple Myeloma.&#xD;
      Smoldering Multiple Myeloma is an early precursor to a rare blood cancer known as Multiple&#xD;
      Myeloma, which affects plasma cells. The study will test two different combinations of the&#xD;
      study drugs; a combination of the vaccine (PVX-410) along with Citarinostat (CC-96241) and&#xD;
      triple combination of the vaccine, Citarinostat, and Lenalidomide.&#xD;
&#xD;
      The vaccine (PVX-410) is a multi-peptide vaccine that contains four synthetic peptides that&#xD;
      together are intended to induce a T cell-mediated immune response against the myeloma. The&#xD;
      FDA (the U.S. Food and Drug Administration) has not approved PVX-410 as a treatment for any&#xD;
      disease.&#xD;
&#xD;
      Citarinostat is an orally active, small-molecule Histone Deacetylase (HDAC) Inhibitor which&#xD;
      is being combined here to further augment the immune activity of the vaccine. Citarinostat&#xD;
      has not been approved by the FDA as a treatment for any disease.&#xD;
&#xD;
      Lenalidomide is commercially available analogue of thalidomide with immunomodulatory,&#xD;
      antiangiogenic, and antineoplastic properties that has demonstrated an increase in immune&#xD;
      activity in previous trials. The FDA has approved Lenalidomide as a treatment option for&#xD;
      Smoldering Multiple Myeloma. Lenalidomide is being added to the combination of the vaccine&#xD;
      and Citarinostat because it is hypothesized that co-administration of lenalidomide along with&#xD;
      Citarinostat would further enhance the T cell-mediated immune response induced by PVX-410.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety And Tolerability Of The PVX-410 Tumor Vaccine Regimen</measure>
    <time_frame>2 years</time_frame>
    <description>The proportion of participants who experience dose limiting toxicities and other toxicities. The CTCAE version 4 criteria will be used to grade adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Responses Of Lymphocytes To HLA A2+</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change In Monoclonal (M) Serum Protein</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change In Free Light Chain (FLC)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change In Urinary FLC Level</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Immune Response and Clinical Anti-tumor Responses</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Smoldering Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>PVX-410 + Citarinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive:&#xD;
6 biweekly doses of PVX-410&#xD;
6 biweekly doses of Hiltonol&#xD;
3 monthly cycles of Citarinostat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PVX-410 + Citarinostat + Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive:&#xD;
6 biweekly doses of PVX-410&#xD;
6 biweekly doses of Hiltonol&#xD;
3 monthly cycles of Citarinostat&#xD;
3 monthly cycles of Lenalidomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hiltonol</intervention_name>
    <description>Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration</description>
    <arm_group_label>PVX-410 + Citarinostat</arm_group_label>
    <arm_group_label>PVX-410 + Citarinostat + Lenalidomide</arm_group_label>
    <other_name>Poly ICLC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citarinostat</intervention_name>
    <description>Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.</description>
    <arm_group_label>PVX-410 + Citarinostat</arm_group_label>
    <arm_group_label>PVX-410 + Citarinostat + Lenalidomide</arm_group_label>
    <other_name>CC-96241</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.</description>
    <arm_group_label>PVX-410 + Citarinostat + Lenalidomide</arm_group_label>
    <other_name>REVLIMID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PVX-410</intervention_name>
    <description>PVX-410 Biweekly (0.8 mg) via subcutaneous injection</description>
    <arm_group_label>PVX-410 + Citarinostat</arm_group_label>
    <arm_group_label>PVX-410 + Citarinostat + Lenalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has confirmed SMM according to a definition derived from the International&#xD;
             Myeloma Working Group (IMWG) definition (International Working Group, 2003): serum&#xD;
             M-protein ≥3 g/dL or BMPC &gt;10%, or both, along with normal organ and marrow function&#xD;
             (CRAB) within 4 weeks before baseline.&#xD;
&#xD;
               -  C: Absence of hypercalcemia, evidenced by a calcium &lt;10.5 mg/dL.&#xD;
&#xD;
               -  R: Absence of renal failure, evidenced by a creatinine &lt; 1.5 mg/dL (177 µmol/L)&#xD;
                  or calculated creatinine clearance (using the Modification of Diet in Renal&#xD;
                  Disease [MDRD] formula) &gt;50 mL/min.&#xD;
&#xD;
               -  A: Absence of anemia, evidenced by a hemoglobin &gt;10 g/dL.&#xD;
&#xD;
               -  B: Absence of lytic bone lesions on standard skeletal survey.&#xD;
&#xD;
          -  Patient is at higher than average risk of progression to active MM, defined as having&#xD;
             2 or more of the following features:&#xD;
&#xD;
               -  Serum M-protein ≥3 g/dL.&#xD;
&#xD;
               -  BMPC &gt;10%.&#xD;
&#xD;
               -  Abnormal serum FLC ratio (0.26-1.65).&#xD;
&#xD;
          -  Patient is aged 18 years or older.&#xD;
&#xD;
          -  Patient has a life expectancy of greater than 6 months.&#xD;
&#xD;
          -  Patient is HLA-A2+&#xD;
&#xD;
          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Patient has adequate bone marrow function, evidenced by a platelet count ≥75×109/L and&#xD;
             an absolute neutrophil count (ANC) ≥1.0×109/L within 2 weeks before baseline.&#xD;
&#xD;
          -  Patient has adequate hepatic function, evidenced by a bilirubin ≤2.0 mg/dL and an&#xD;
             alanine transaminase (ALT), and aspartate transaminase (AST) ≤2.5×ULN within 2 weeks&#xD;
             before baseline.&#xD;
&#xD;
          -  If of child-bearing potential, patient agrees to use adequate birth control measures&#xD;
             during study participation.&#xD;
&#xD;
          -  If a female of child-bearing potential , patient has negative serum pregnancy test&#xD;
             results within 2 weeks before baseline and is not lactating.&#xD;
&#xD;
          -  If assigned to receive lenalidomide and a female of reproductive potential, must&#xD;
             adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.&#xD;
&#xD;
          -  If assigned to receive lenalidomide, patient must be registered into the mandatory&#xD;
             Revlimid REMS® program and be willing and able to comply with the requirements of the&#xD;
             REMS® program.&#xD;
&#xD;
          -  Patient (or his or her legally accepted representative) has provided written informed&#xD;
             consent to participate in the study.&#xD;
&#xD;
          -  Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has symptomatic MM, as defined by any of the following:&#xD;
&#xD;
               -  Lytic lesions or pathologic fractures.&#xD;
&#xD;
               -  Anemia (hemoglobin &lt;10 g/dL).&#xD;
&#xD;
               -  Hypercalcemia (corrected serum calcium &gt; 11.5 mg/dL).&#xD;
&#xD;
               -  Renal insufficiency (creatinine &gt; 1.5 mg/dL).&#xD;
&#xD;
               -  Other: symptomatic hyperviscosity, amyloidosis.&#xD;
&#xD;
          -  Patient has a history of a prior malignancy within the past 3 years (excluding&#xD;
             resected basal cell carcinoma of the skin or in situ cervical cancer).&#xD;
&#xD;
          -  Patient has abnormal cardiac status, evidenced by any of the following:&#xD;
&#xD;
               -  New York Heart Association (NYHA) stage III or IV congestive heart failure (CHF).&#xD;
&#xD;
               -  Myocardial infarction within the previous 6 months.&#xD;
&#xD;
               -  Symptomatic cardiac arrhythmia requiring treatment or persisting despite&#xD;
                  treatment.&#xD;
&#xD;
          -  Patient is receiving any other investigational agent.&#xD;
&#xD;
          -  Patient has a current active infectious disease or positive serology for human&#xD;
             immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), or&#xD;
             hepatitis A virus (HAV).&#xD;
&#xD;
          -  Patient has a history of or current auto-immune disease.&#xD;
&#xD;
          -  Patient has been vaccinated with live attenuated vaccines within 4 weeks before study&#xD;
             vaccination.&#xD;
&#xD;
          -  Any previous treatment with a HDAC inhibitor, including Citarinostat.&#xD;
&#xD;
          -  Had involvement in the planning and/or conduct of the study by association with the&#xD;
             Sponsor, study drug supplier(s) or study center or was previously enrolled in the&#xD;
             present study.&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 28 days before the first&#xD;
             dose of treatment, with the exceptions of intranasal and inhaled corticosteroids or&#xD;
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of&#xD;
             prednisone, or an equivalent corticosteroid.&#xD;
&#xD;
          -  Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3&#xD;
             electrocardiograms (ECGs) using Frediricia's Correction.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, active peptic ulcer disease or gastritis, active bleeding diatheses,&#xD;
             or psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements or compromise the ability of the patient to give written informed consent&#xD;
&#xD;
          -  Known history of previous clinical diagnosis of tuberculosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noopur Raje, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noopur Raje, MD</last_name>
    <phone>617-726-0711</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts general Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noopur Raje, MD</last_name>
      <phone>617-726-0711</phone>
    </contact>
    <investigator>
      <last_name>Noopur Raje, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Avigan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Richardson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Gasparetto, MD</last_name>
      <email>cristina.gasparetto@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Cristina Gasparetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cleveland- Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ehsan Malek, MD</last_name>
      <email>Eshan.malek@uhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Ehsan Malek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Noopur Raje</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Smoldering Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
    <mesh_term>Citarinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

